Skip to content

Treating Subthreshold Depression in Primary Care: A Randomized Controlled Trial of Behavioral Activation With Mindfulness.

Samuel Y S Wong, Yu Ying Sun, Aaroy T Y Chan, Maria K W Leung, David V K Chao, Carole C K Li, King K H Chan, Wai Kwong Tang, Trevor G. Mazzucchelli, Alma M L Au, Benjamin H K Yip

Annals of family medicine March 1, 2018 DOI: 10.1370/afm.2206 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 231
Population Adults aged 18 years or older with subthreshold depression recruited from public primary care clinics in Hong Kong
Intervention Group-based behavioral activation with mindfulness (BAM)
Duration Eight 2-hour weekly sessions; outcomes assessed at baseline, end of intervention, 5 months, and 12 months
Measures Beck Depression Inventory-II
Topics Depression Meditation
Keywords Humans Logistic models Quality of life Adult Middle aged Cost-benefit analysis Primary health care Hong kong Female Prevention Randomized controlled trial Primary care Behavioral activation Subthreshold depression
Key findings Group behavioral activation with mindfulness produced a modestly greater reduction in depressive symptoms than usual care at 12 months (between-group mean difference -3.85 on the Beck Depression Inventory-II; Cohen d -0.46) and a lower incidence of major depressive disorder (10.8% vs 26.8%). Other secondary outcomes did not differ significantly. The authors conclude the intervention appears efficacious, though generalizability may be limited.

Abstract

Purpose: We undertook a randomized controlled trial to assess the efficacy of group-based behavioral activation with mindfulness (BAM) for treating subthreshold depression in primary care in Hong Kong.

Methods: We recruited adult patients aged 18 years or older with subthreshold depression from public primary care clinics and randomly assigned them to a BAM intervention group or a usual care group. The BAM group was provided with eight 2-hour weekly BAM sessions by trained allied health care workers. Patients in the usual care group received usual medical care with no additional psychological interventions. The primary outcome was depressive symptoms measured by the Beck Depression Inventory-II at 12 months. Secondary outcomes included incidence of major depressive disorder at 12 months. We assessed quality of life, activity and circumstances change, functional impairment, and anxiety at baseline, end of intervention, 5 months, and 12 months.

Results: We randomly allocated 115 patients to the BAM intervention and 116 patients to usual care. At 12 months, compared with usual care peers, BAM patients had a slightly more favorable change in levels of depressive symptoms on the Beck Depression Inventory-II (between-group mean difference in score = -3.85; 95% CI, -6.36 to -1.34; Cohen d = -0.46, 95% CI, -0.76 to -0.16). Incidence of major depressive disorder was lower with BAM (10.8% vs 26.8%, P = .01), whereas groups did not differ significantly on other secondary outcomes at 12 months.

Conclusions: Group BAM appears to be efficacious for decreasing depressive symptoms and reducing the incidence of major depression among patients with subthreshold depression in primary care, although generalizability of our findings may be limited.

Comparable studies

Other randomized controlled trials on depression, most cited first.

Study Year Design Participants
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Subjects with DSM-IV major depression (treatment resistant) 2006 Randomized, placebo-controlled, double-blind crossover study n = 18
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Cited by 7

and 2 more in the library

Cites 3

Explore topics